If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
The role of APOE in the risk of Alzheimer's disease (AD) has largely focused on its effects on AD pathological processes. However, there are increasing data that APOE genotype affects processes in normal brains. Studies of young cognitively normal humans show effects of APOE genotype on brain structure and activity. Studies of normal APOE knock-in mice show effects of APOE genotype on brain structure, neuronal markers, and behavior. APOE interactions with molecules important for lipid efflux and lipid endocytosis underlie effects of APOE genotype on neuroinflammation and lipoprotein composition. These effects provide important targets for new therapies for reduction of the risk of AD before any signs of pathogenesis.
). Thus, there are nearly 80 million people in the US who carry this risk, without any risk-altering treatments. APOE2, in contrast, lowers the AD risk in about 35 million US individuals. The main questions that these observations raise are: how does APOE genotype affect the risk of AD, and what can be done to decrease that risk in individuals? In this review, we will be examining whether the roles of APOE in neuroinflammation or lipid homeostasis before AD pathogenesis may predispose the brain to damage that occurs later in aging with the accumulation of the Aβ peptide.
THE EFFECTS OF APOE GENOTYPE ON INFLAMMATION
Inflammation is a potential early indicator of AD risk or AD onset in humans because genetic factors related to immune functions and inflammation have been identified in genome-wide association studies of AD (
). APOE is one of these AD risk genes related to neuroinflammation, as evidenced by several in vitro and in vivo systems. In vivo studies rely largely on mice with the coding sequence of the human APOE alleles replacing the mouse APOE gene as the best animal model for normal APOE regulation and function (
Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.
) compared with APOE2 and APOE3 mice. APOE4 mice are also more susceptible to brain damage that has strong inflammatory components, such as traumatic brain injury (
). In APOE mouse models, peptides based on the APOE receptor binding domain prevent or alleviate effects of inflammation-related insults, such as lipopolysaccharide-induced inflammation (
). Similar effects are seen in vitro. APOE isoforms affect inflammatory processes in microglia and astrocytes, with APOE4 promoting the strongest inflammatory effects (
), suggesting that APOE levels and inflammation are in a negative feedback loop, with APOE inhibiting inflammation and inflammation inhibiting APOE levels. These data indicate that APOE is associated with increased inflammatory responses before and after the onset of AD pathogenesis.
THE EFFECTS OF APOE GENOTYPE ON LIPID HOMEOSTASIS
APOE is one of the primary apolipoproteins in CNS lipid metabolism (
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.
). Thus, an effect of APOE genotype on brain lipid homeostasis may underlie the AD risk associated with APOE. As with inflammation, this possibility is supported by the identification of lipid-related genetic risk factors for AD (
). Although APOJ is not as strong of a genetic risk factor as APOE [the polymorphic site in APOJ has an odds ratio of about 0.9 for the minor allele, compared with an odds ratio of about 5 for the APOE-ε4 allele (
Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (−/−) mice but impaired clearance of axonal degeneration products following injury.
) in the brain. APOE isoforms differ in their ability to promote cholesterol efflux from cells, with APOE2 having the greatest efficiency and APOE4 the least (
Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
). The relevance of these findings to humans was demonstrated through analysis of human cerebrospinal fluid (CSF), with APOE complexes largest in APOE2.3 individuals and smallest in APOE4.4 individuals (
). Consistent with the hypothesis that APOE4 is associated with smaller lipoproteins, APOE4 lipoproteins promoted less cholesterol efflux than APOE3 lipoproteins (
). The need for clearance of lipids from the brain may increase with age as membrane damage accumulates and neuronal loss occurs.
The effects of the reduced lipidation capacity of APOE4 may result in reduced neuronal protection or repair. Neuronal injury increases brain APOE levels (
). We hypothesize that reduced lipidation of CNS lipoproteins may be an important risk factor of AD; biomarker-based APOE lipidation may be useful in measuring levels of neuroprotection in the brain environment (
). The effects of APOE genotype on lipidation may be causally related to some effects of inflammation, due to direct effects on high levels of cholesterol on inflammation (
THE EFFECTS OF APOE GENOTYPE ON APOE LEVELS AND POSTTRANSLATIONAL MODIFICATION
Humans with the APOE4 allele have smaller APOE lipoproteins and lower APOE levels in the CSF and plasma, whereas those with the APOE2 allele have larger APOE lipoproteins and higher APOE levels (
). If APOE4 individuals have both smaller lipoproteins and less APOE, then there could be a twofold impact on lipid clearance and delivery processes that contributes to the increased risk for AD.
There are also important posttranslational modifications to the APOE protein. Most notably, APOE4 lacks cysteine residues for the formation of APOE-APOE homodimers and APOE-APOAII heterodimers (
), whereas APOE3 contains one cysteine and APOE2 contains two cysteines for dimer formation. APOE4 is associated with enhanced cleavage of the C terminus of APOE (
C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice.
). We have identified biochemical differences in modified versions of brain APOE: unmodified APOE is solubilized only in the presence of detergent and modified APOE is solubilized in saline (
). The APOE isoform effects on APOE levels and on dimer formation support loss-of-function explanations for the effects of APOE4, with APOE4 less able to clear debris and deliver lipids than APOE2 or APOE3. In contrast, effects of APOE cleavage fragments on neurotoxicity (
) support a gain-of-function explanation. Understanding of APOE functions requires a better understanding of the different forms of APOE present in the CNS, particularly because treatment approaches could involve the increase or the decrease of APOE4 levels.
THE EFFECTS OF APOE GENOTYPE ON NORMAL CNS FUNCTIONS
APOE genotype affects a number of CNS phenotypes in young individuals, as demonstrated both in mice and in humans (
). APOE4 knock-in mice have several differences compared with APOE3 mice. In measures of behavior, APOE4 is associated with deficits in spatial learning and memory (
). In measures of human brain activity using functional magnetic resonance imaging, APOE4 is associated with increased brain activity in the default mode network, and the hippocampus during an encoding task (
). APOE genotype in the absence of AD is also associated with differences in brain structure. APOE4 is associated with differences in the MTL at birth (
). Differences in brain structure in APOE4 individuals are also supported by the observation that dendritic spine density in the hippocampus is lower in aged APOE4 individuals with no evidence of Aβ deposition (
). Some of these differences are consistent with increased brain activity or connectivity in young individuals with APOE4. The antagonistic pleiotropy hypothesis posits that APOE4 has a positive effect on brain activity and behavior at young ages, but is detrimental at older ages (
). In general, the human studies and mouse studies together have supported the hypothesis that APOE genotype impacts normal brain structure and function independent of AD pathology.
APOE-DIRECTED PREVENTATIVE TREATMENTS
Understanding of the basic biology of APOE helps to identify mechanism-based therapies that could rescue APOE4 phenotypes. In normal brains, these phenotypes could predispose to Aβ deposition with aging, which could be prevented by early prophylactic approaches. For example, as mentioned above, APOE mimetic peptides could serve as a therapeutic approach for APOE4 individuals for AD, as well as other diseases with neuro-inflammatory components (
Another potential AD preventative treatment is the class of nonsteroidal anti-inflammatory drugs (NSAIDs). Epidemiological studies have repeatedly shown that early NSAID use is associated with reduced AD risk in humans (
). We have tested this hypothesis by treating APOE4 mice with the NSAID, ibuprofen. Ibuprofen rescues the effects of APOE4 genotype on reduced dendritic spine density and on the altered distribution of APOE in brain fractions (
). These effects of ibuprofen support the epidemiological data that NSAIDs may reduce AD risk factors in normal individuals.
Yet another approach is to counteract the effects of APOE4 genotypes on the deficient APOE levels and reduced APOE4 lipidation. APOE and related molecules are regulated as part of the LXR/RXR transcriptional system, making that an attractive target for drug discovery (
). LXR activation promotes brain lipid efflux through induction of genes, such as APOE and ABCA1, and, in mouse models, leads to a decrease in lipids in synaptosomes (
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.
). Finally, induction of ABCA1 activity could be a useful AD therapeutic approach: an agonist for ABCA1 reversed the effects of APOE4 on reduced lipoprotein lipidation, synaptic markers, and behavioral deficits (
). Specifically increasing the function of ABCA1 is a particularly interesting approach to altering APOE lipid metabolism, because it relies only on promoting lipid efflux through ABCA1, and not induction of the other genes of the LXR transcription system (
The unparalleled effect of APOE on AD risk in older individuals and its varied effects on the function of younger brains emphasize the need to study AD prevention strategies related to APOE. Studies on APOE in inflammation and lipid homeostasis are providing mechanisms for how brain alterations associated with APOE4 might be rescued (Fig. 1). The many people who have inherited this strong predisposition to AD have no treatments to help them avoid AD and, with increased access to genome sequencing, more of them are recognizing that they are at frighteningly high risk. This population of APOE4-positive individuals provides a logical target for in-depth studies of promising AD prevention approaches that are not necessarily related to the neuropathological accumulation of Aβ (
). While prevention approaches to AD are difficult to evaluate, given the need to measure long-term effects, they provide hope if the approaches of treating individuals after the onset of AD pathogenesis are unsuccessful.
Fig. 1CNS APOE functions. CNS APOE (in blue) is secreted from glia. It is lipidated through interactions with ABCA1 on neurons and glia, forming high-density CNS lipoproteins (in yellow). These lipoproteins can deliver lipids to neurons to promote neuronal complexity. Compared with APOE3, APOE4 is less able to promote cholesterol efflux, forming smaller CNS lipoproteins, and less able to deliver lipids to neurons for neuroprotective functions. APOE lipoproteins also inhibit glial inflammation, with the smaller and fewer APOE4 lipoproteins less capable of this function. Chronic glial inflammation in the APOE4 brain contributes to neuronal dysfunction and impaired APOE regulation, but these APOE4 phenotypes can be mitigated through treatments with anti-inflammatory agents (NSAID).
Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.
Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (−/−) mice but impaired clearance of axonal degeneration products following injury.
Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice.
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.
33777-9&id=gr1.jpg){kind=link}